上市后三季报首亏 新诺威遇转型阵痛

Core Insights - Newnow's performance has been under pressure since its transition to innovative drugs, resulting in its first quarterly loss since going public in 2019, with a net profit of -24.05 million yuan for the first three quarters of this year, a year-on-year decline of 117.26% [1][2] Financial Performance - The sales expenses for Newnow increased by 87.12% to 202 million yuan, primarily due to increased marketing investments in the biopharmaceutical sector [2] - Research and development expenses rose by 49.56% to 683 million yuan, driven by Giant Stone Biotech's increased investment in R&D [2] - Newnow's net cash flow from operating activities was -175 million yuan for the first three quarters [4] Strategic Moves - Newnow is planning to further acquire a 29% stake in Giant Stone Biotech for 1.1 billion yuan, increasing its ownership from 51% to 80% [2] - The company aims to list on the Hong Kong Stock Exchange to enhance its global strategy and improve its capital operation platform [4] Market Performance - Newnow's stock price experienced significant volatility, with a cumulative increase of 134.65% from January 2 to June 6, followed by a decline of 47.89% from June 9 to November 5 [5] - As of November 5, Newnow's stock closed at 32.6 yuan per share, with a total market capitalization of 45.79 billion yuan [6] Management Issues - The former chairman of Newnow, Pan Weidong, was penalized for insider trading, leading to his resignation [7] - A planned acquisition of Shiyao Baike was ultimately terminated in April, indicating challenges in the company's strategic initiatives [8]